1_2.eps

Size: px

Start display at page:

Download "1_2.eps"

しゅんすけのしろ
7 years ago
Views:

1 第32回日本頭頸部癌学会ランチョンセミナー6 Pre-Meeting Abstract FDG-PET の頭頸部癌における臨床的有用性司会長放射線治療センター長講演 1 耳鼻咽喉科部長講演 2 PETセンター長岡村光英先生日時 2008年6月13日金 12:00 13:00 会場ハイアットリージェンシー東京共催第32回日本頭頸部癌学会日本メジフィジックス株式会社東京都江東区新砂3丁目4番10号 TEL 代作成 AB-0805-G01 B会場

1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 13) 14) 15) 16) 17) 18) 19) 20) Nakasone Y et al. The role of whole-body FDG-PET in preoperative assessment of tumor staging in oral cancers.

Why most PET of lung and head-and-neck cancer will be PET/CT. J Nucl Med 2004: 45 Suppl: 66S-71S. Schoder H et al. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion.

Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 2006; 65: 143-151. Gordin A et al.

Laryngoscope 2006; 116: 273-278. Schmid DT et al. Impact of positron emission tomography in the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck.

10 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 13) 14) 15) 16) 17) 18) 19) 20) Nakasone Y et al. The role of whole-body FDG-PET in preoperative assessment of tumor staging in oral cancers. Ann Nucl Med 2001; 15: Schwartz DL et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arc Otolaryngol Head Neck Surg 2004; 130: Goerres GW et al. Why most PET of lung and head-and-neck cancer will be PET/CT. J Nucl Med 2004: 45 Suppl: 66S-71S. Schoder H et al. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004; 231: Schwartz DL et al. FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. Head and Neck 2005; 27: Wang D et al. Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 2006; 65: Gordin A et al. Fluorodeoxyglucose-positron emission tomography/computed tomography imaging in patients with carcinoma of the larynx: Diagnostic accuracy and impact on clinical management. Laryngoscope 2006; 116: Schmid DT et al. Impact of positron emission tomography in the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck. Laryngoscope 2003; 13: Goerres GW. Clinical molecular anatomic imaging. Philadelphia,Lippincott Williams & Wilkins 2003; Ng SH et al. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: A prospective study of 124 patients with histologic correlation. J Nucl Med 2005; 46: Chang JTC et al. Nasopharyngeal carcinoma staging by 18F-fluorodeoxyglucose positron emission tomography. Int J Radiation Oncol Biol Phys 2005; 62: Stokkel MPM et al. 18F-fluorodeoxyglucose dual-head positron emission tomography as a procedure for detecting simultaneous primary tumors in cases of head and neck cancer. Cancer 1999; Regelink G et al. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modarities. Eur J Nucl Med 2002; 29: Rusthoven KWE et al. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 2004; 101: Lonneux M et al. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope 2000; 110: Greven KM et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001; 23: Kitagawa Y et al. FDG-PET for prediction of tumour aggresiveness and response to intra-arterial chemotherapy and in head and neck cancer. Eur J Nucl Med Imaging 2003; 30: Kubota K et al. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT: Eur J Nucl Med Mol Imaging 2004; 31: Nakamoto Y et al. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology 2005; 234: ,,. FDG-PET. 2005; ,.

11 FAQ

12 MEMO MEMO

untitled

untitled 260 250 200 150 10 100 50 0 1960 1965 1970 1975 1980 1985 1985 1995 2000 2005 25% 56% 66% 60% 90 80 70 60 50 40 30 20 10 0 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 4 1999 1990 2003 2005 2010 500,000 70,000 100,000